Soon-Shiong back to his roots: NantWorks acquires next-gen Abraxane in potential $1.3B deal
Billionaire investor Patrick Soon-Shiong buys the rights to a next-gen Abraxane from Sorrento Therapeutics - building on the drug that launched his own fortune.